FDA Grants Orphan Drug Designation to Debio 1143
News Jun 02, 2016
Debiopharm International SA (Debiopharm) has announced that the FDA Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to Debio 1143 for treatment of Ovarian Cancer. Orphan Drug Designation by the FDA provides regulatory and financial incentives to develop therapies for life-threatening or chronically debilitating conditions affecting fewer than 200 000 people in the US, or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug, and for which no satisfactory treatment is available.
Debio 1143 is an oral, small molecule inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with a dual pro-apoptotic and immunomodulatory mode of action developed as a potent chemo/radio-sensitizer in oncology. Further to the encouraging signs of efficacy seen in clinical phase I and supported by this significant regulatory milestone, Debiopharm will soon expand the clinical development of this therapy to patients with ovarian cancer.
"Obtaining orphan designation for Debio 1143 in the United States is an important regulatory milestone", stated Peggy Lipp, Director, Regulatory Affairs, Business Intelligence & Market Access, Debiopharm International S.A. "It speaks to the need for new treatment options in this chronically debilitating and life threatening condition and the potential role of Debio 1143's mode of action. This orphan drug designation is a proof of our commitment to developing innovative therapies for oncology patients".
New Microscope Captures Detailed 3-D Movies of Cells Deep Within Living SystemsNews
Merging lattice light sheet microscopy with adaptive optics reveals the most detailed picture yet of subcellular dynamics in multicellular organisms.READ MORE
Reversing an Unstoppable Cancer Cascade with ProteomicsNews
Mutations in genes that produce RAS proteins turn a normally benign process, essential for cellular growth, into a cancer stimulant that is currently undruggable. Now, cutting-edge protein analysis may help treat cancers caused by these mutations.READ MORE
A New, Streamlined Approach to Diagnosing and Treating Bowel CancerNews
Researchers at the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide have discovered a faster, more cost-effective way to determine which DNA mutations cause human bowel cancer.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
29th International Conference on Public Mental Health and Neuroscience
Jul 16 - Jul 18, 2018
International Conference on Epigenetics and Epitranscriptomics
Sep 17 - Sep 18, 2018